BOC Health Care
Executive Summary
Acquires assets relating to DuPont Merck's Brevibloc (esmolol) in the U.S., Canada and Europe for $72.5 mil. The short-acting I.V. beta blocker used in critical care settings will be marketed by BOC pharmaceutical division Anaquest in North America and Europe; Dupont Merck will retain rights to market the product in the rest of the world. Worldwide sales of Brevibloc were about $15 mil. in 1992.